SABCS 2020 Highlights

Health-Related Quality of Life in Patients with Metastatic Breast Cancer and Brain Metastases Treated with Tucatinib in Combination with Trastuzumab plus Capecitabine

Conference Correspondent - SABCS 2020 Highlights

NALA Phase 3 Trial Outcomes in Patients Treated with Neratinib or Lapatinib

Conference Correspondent - SABCS 2020 Highlights

HER2CLIMB-02: A Randomized, Double-Blind, Phase 3 Study of Tucatinib with T-DM1 for the Treatment of Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer

Conference Correspondent - SABCS 2020 Highlights

Final Overall Survival Analysis from the Randomized Phase 3 ExteNET Trial of Neratinib in Patients with HER2-Positive Early-Stage Breast Cancer

Conference Correspondent - SABCS 2020 Highlights

Hormone Receptor Status Is Not a Factor in the HER2CLIMB Study of Tucatinib Combination Treatment for Patients with HER2-Positive Metastatic Breast Cancer

Conference Correspondent - SABCS 2020 Highlights

Comparison of ARX788 and Lapatinib/Capecitabine in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer

Conference Correspondent - SABCS 2020 Highlights

Efficacy, Safety, and Tolerability of Tucatinib in Combination with Letrozole and Palbociclib in Patients with HR-Positive, HER2-Positive Metastatic Breast Cancer

Conference Correspondent - SABCS 2020 Highlights

Use of Circulating Tumor Cells to Guide Treatment with HER2 Therapy

Conference Correspondent - SABCS 2020 Highlights

Real-World Analysis of Outcomes in Older Women with HER2-Positive Advanced Breast Cancer

Conference Correspondent - SABCS 2020 Highlights

Effect of Brain Metastases in Real-World Treatment Patterns and Healthcare Resource Utilization Among HER2-Positive Metastatic Breast Cancer Patients

Conference Correspondent - SABCS 2020 Highlights

Results 1 - 10 of 10

To sign up for our newsletter or print publications, please enter your contact information below and click "Subscribe".

I'd like to receive:

TOP Print Edition

TOP Weekly e‑Newsletter

I have reviewed and consent to the terms of TOP's Privacy Policy, and TOP has my permission to retain my information in its database, and to forward pertinent communications to me.